Clinical trials: Glioma, Malignant
Brain and Central Nervous System Tumors
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00052455
- Testing
- lomustine, procarbazine hydrochloride, temozolomide
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Diffuse Intrinsic Pontine Glioma, High Grade Glioma
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
In this study, there are two treatment groups called Cohort 1 and Cohort 2. Cohort 1 is for patients with diffuse midline glioma, diffuse intrinsic pontine glioma, medulloblastoma, or another rare high-grade glioma that expresses…
- Conditions
- Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor, Ependymal Tumor
- Trial name
- NCT04099797
- Testing
- C7R-GD2.CART cells (IV and ICV infusion)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Baylor College of Medicine
High Grade Glioma, Glioblastoma
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.
- Trial name
- NCT05565118
- Testing
- Standard Surgical Treatment, Intraoperative Electrocorticography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Glioblastoma
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
- Trial name
- ASPIRE (NCT06389591)
- Testing
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
High-grade Glioma
Nurse-led Family and Network Consultations
Patients diagnosed with high-grade gliomas (HGG) experience a complex symptom burden including high-levels concerns. As a consequence to this life-threatening disease, the rely on close contact with a specialized…
- Trial name
- CARES (NCT03458312)
- Testing
- Family and Network Consultations
- Where
- Denmark
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Glioma
Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
This research study is testing the safety of a vaccination of cells called GM-K562 cells mixed with the participants own irradiated tumor cells.
- Trial name
- NCT00694330
- Testing
- GM-K562 Vaccination
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Malignant Glioma
Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 12 months, with 90 - 95% of patients surviving less than 2 years.
- Trial name
- Gliadel Wafer (NCT00576446)
- Testing
- Dendritic cell Vaccine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Cedars-Sinai Medical Center
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00369590
- Testing
- ziv-aflibercept, pharmacological study, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients
Family caregivers of patients with a primary brain tumor experience a high caregiving load including assistance with activities of daily living without any formal training.
- Trial name
- NCT05511324
- Testing
- Questionnaires, Caregiver Assessment
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV
International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
The HIT-HGG-2013 trial offers an innovative high-quality diagnostics and science program for children and adolescents >3 years, suffering from one of the following types of high grade gliomas: 1.
- Conditions
- Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma
- Trial name
- HIT-HGG-2013 (NCT03243461)
- Testing
- Temozolomide + Valproic Acid
- Where
- 51 sites in Germany
- Volunteers
- 167 people
- Sponsor
- University of Göttingen
Brain and Central Nervous System Tumors
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent…
- Trial name
- NCT00002986
- Testing
- carmustine, topotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Glioma, Glioblastoma
Image Guided Reirradiation of High-grade Glioma
The purpose of the study is to evaluate the short- and long term toxicity of radiotherapy to patients with recurrent high-grade glioma who have previously received radiotherapy and to determine the best dose and treatment…
- Trial name
- NCT02025231
- Testing
- External beam radiotherapy
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 31 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Recurrent Glioblastoma, Recurrent High-grade Glioma
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
The goal of this study is to learn about a type of brain cancer called high-grade glioma. This study is for people who have previously received treatment for brain cancer, but the cancer has come back or gotten worse after…
- Trial name
- NCT06501911
- Testing
- Bicalutamide, Intensity-modulated radiation therapy (IMRT)
- Where
- United States
- Sponsor
- University of Nebraska
Brain Tumor
Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.
This study is designed to assess the safety and tolerability, pharmacokinetic profiles, immunogenicity of GB222 in Chinese patients with relapsed/progressive high-grade glioma; moreover, changes in cerebral edema, changes in KPS…
- Trial name
- NCT04178057
- Testing
- GB222 3mg/kg, GB222 5mg/kg, GB222 7.5mg/kg
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Genor Biopharma Co., Ltd.
Malignant Glioma
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after radiotherapy.
- Trial name
- NCT04197492
- Testing
- Hypofractionated Stereotactic Radiotherapy, Anlotinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Huashan Hospital
High Grade Glioma
Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma.
- Trial name
- NCT00826930
- Testing
- Trans Sodium Crocetinate (TSC)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Brain and Central Nervous System Tumors
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given…
- Trial name
- NCT00509431
- Testing
- Erlotinib + Sirolimus
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain Tumors
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid…
- Trial name
- NCT00528437
- Testing
- temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.